Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …

Abstract Background Treatment-resistant Depression (TRD) represents a widespread
disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer …

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …

Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …

Comment 978 www. thelancet. com/psychiatry Vol 6 December 2019 from the phase 3
clinical trials, which are freely available in the public domain in the form of the slides and …

Glutamate (Glu) and gamma-aminobutyric acid (GABA) are implicated in the
pathophysiology of major depressive disorder (MDD). GABA levels or GABAergic …

The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine,
an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important …

One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Background: Successful treatment of major depressive disorder (MDD) can be challenging,
and failures (" treatment-resistant depression"[TRD]) are frequent. Steps to address TRD …